High Quality Evidence of Chinese Lupus Nephritis (HELP)

NCT03001973 · tracked via the Priya Life Science China tracker

Sponsor

Sun Yat-sen University

Phase

Observational

Started

2013-11

Last updated

2026-09-15

Condition(s) studied

Lupus Nephritis

Investigational drug(s) / intervention(s)

No Intervention

No Intervention: Registration of all LN patients in the First Affiliated Hospital of Sun Yat-sen University and other hospitals which have signed the contract in China.

Study summary

The investigators are registering LN patients at recruited hospitals and developing a LN database in China. Patients will be follow-up every year, and both baseline and follow-up information will be entered into the registration system.

Eligibility

Sex

ALL

Min age

14 Years

Max age

—

Healthy volunteers

Inclusion Criteria: * Patients who diagnosis as lupus nephritis Exclusion Criteria: * No

Primary outcome measure(s)

All-cause mortality and cardiovascular mortality of LN patients — 10years
A composite renal outcome of LN patients — 10years
The composite renal outcome defined as doubling of serum creatinine and ESRD (defined as initiation of dialysis or kidney transplantation).

Trial sites (1)

Facility	City	Region	Status
The First Affiliated Hospital, Sun Yat-sen University	Guangzhou	Guangdong	Recruiting

More Sun Yat-sen University trials in China

ACHP-THP vs EC-THP as Neoadjuvant Therapy for HER2-positive EBC Active, not recruiting

Combination of Concurrent Chemoradiotherapy With Surufatinib and Tislelizumab in Patients With Locally Advanced Non-Small Cell Lung Cancer Recruiting

Sintilimab and Linperlisib Combination Treatment in Relapsed or Refractory Extranodal Natural Killer/T Cell Lymphoma Recruiting

Phacotrabeculectomy Versus Phacogoniotomy (PVP) in Advanced Primary Angle-closure Glaucoma Active, not recruiting

Myeloprotection With Trilaciclib in Pan-cancer Population Starting soon

Other trials for the same condition

Phase 3 Study of Anifrolumab in Adult Patients With Active Proliferative Lupus Nephritis Active, not recruiting

UB-VV410 in Subjects With Active Refractory Systemic Lupus Erythematosus or Lupus Nephritis Recruiting

A Trial to Explore the Efficacy and Safety of O-triple as Initial Therapy in the Active Lupus Nephritis Patients (INITIAL Trial) Starting soon

CHT105 for the Treatment of Refractory Lupus Nephritis Enrolling by invitation

CD19/BCMA CAR-T Cell Therapy for Refractory/Relapsed Lupus Nephritis Recruiting

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT03001973 on ClinicalTrials.gov ↗ ← All trials in China